Clinical Trial Update: Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Lutathera (Lutetium-177 DOTATATE) for inoperable pheochromocytoma and paraganglioma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Neoplasms
• Neuroendocrine Tumors
• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Pheochromocytoma, Paraganglioma | Phase 2 | Status: RECRUITING